Cover Image
市場調查報告書

全球皮膚科治療藥市場

Global Dermatological Drugs Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 297494
出版日期 內容資訊 英文 68 Pages
訂單完成後即時交付
價格
Back to Top
全球皮膚科治療藥市場 Global Dermatological Drugs Market 2014-2018
出版日期: 2014年03月07日 內容資訊: 英文 68 Pages
簡介

全球皮膚科治療藥市場,預計從2013年到2018年,以4.29%的年複合成長率擴大。全世界人口高齡化的影響為此成長的背景。還有該市場上生技藥品的利用高漲。

本報告提供全球皮膚科治療藥市場現狀與其預測、市場成長因素與課題、主要供應商的資訊等等,為您概述為以下內容。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 全球乾癬治療藥市場
  • 全球痤瘡治療藥市場
  • 全球皮膚炎治療藥市場
  • 波特的五力分析

第7章 各類型的市場區隔

第8章 地理區分

第9章 購買標準

第10章 罹患率和得病率

  • 乾癬
  • 痤瘡
  • 皮膚炎

第11章 市場成長因素

第12章 成長因素與其影響

第13章 市場課題

第14章 成長因素與課題的影響

第15章 市場趨勢

第16章 趨勢與其影響

第17章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場分析
  • 其他卓越供應商

第18章 主要供應商分析

  • Abbvie Inc.
  • Galderma S.A.
  • Johnson & Johnson Ltd.
  • Novartis International AG
  • Stiefel Laboratories Inc.
  • Valeant Pharmaceuticals International Inc.

第19章 相關報告

目錄
Product Code: IRTNTR3361

TechNavio's analysts forecast the Global Dermatological Drugs market to grow at a CAGR of 4.29 percent over the period 2013-2018. One of the key factors contributing to this market's growth is an increase in the aging population worldwide. The Global Dermatological Drugs market has also been witnessing a spurt in the use of biologics. However, the risk of adverse side effects associated with dermatological drugs could pose a challenge to the growth of this market.

TechNavio's report, the Global Dermatological Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, EMEA and APAC regions; it also covers the Global Dermatological Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors dominating this space include AbbVie Inc., Galderma S.A., Johnson & Johnson Ltd., Novartis AG, Stiefel Laboratories Inc., and Valeant Pharmaceuticals International Inc.

Other vendors mentioned in the report are Actavis plc, Allergan Inc., Almirall SA, Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol Myers Squibb Co., Celgene Corp., Eisai Co. Ltd., Eli Lilly and Co., Genentech Inc., Incyte Corp., Isotechnika Inc., LEO Pharma A/S, Merck & Co. Inc., Mylan Pharmaceuticals Inc., Pfizer Inc., and UCB SA.

Key questions answered in this report:

  • What will the market size and growth rate be in 2018?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by key vendors?
  • What are the strengths and weaknesses of each of these key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Global Psoriasis Drugs Market
    • 06.3.1. Market Size and Forecast
  • 06.4. Global Acne Drugs Market
    • 06.4.1. Market Size and Forecast
  • 06.5. Global Dermatitis Drugs Market
    • 06.5.1. Market Size and Forecast
  • 06.6. Five Forces Analysis

07. Market Segmentation by Type

08. Geographical Segmentation

09. Buying Criteria

10. Rate of Incidence and Prevalence

  • Global Incidence and Prevalence of Psoriasis
  • Global Incidence and Prevalence of Acne
  • Global Incidence and Prevalence of Dermatitis

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

  • 17.1. Competitive Scenario
    • 17.1.1. Key News
    • 17.1.2. Mergers and Acquisitions
  • 17.2. Market Analysis 2013
  • 17.3. Other Prominent Vendors

18. Key Vendor Analysis

  • 18.1. Abbvie Inc.
    • 18.1.1. Business Overview
    • 18.1.2. Key Information
    • 18.1.3. SWOT Analysis
  • 18.2. Galderma S.A.
    • 18.2.1. Business Overview
    • 18.2.2. Key Information
    • 18.2.3. SWOT Analysis
  • 18.3. Johnson & Johnson Ltd.
    • 18.3.1. Business Overview
    • 18.3.2. Business Segmentation
    • 18.3.3. Key Information
    • 18.3.4. SWOT Analysis
  • 18.4. Novartis International AG
    • 18.4.1. Business Overview
    • 18.4.2. Business Segmentation
    • 18.4.3. Key Information
    • 18.4.4. SWOT Analysis
  • 18.5. Stiefel Laboratories Inc.
    • 18.5.1. Business Overview
    • 18.5.2. Key Information
    • 18.5.3. SWOT Analysis
  • 18.6. Valeant Pharmaceuticals International Inc.
    • 18.6.1. Business Overview
    • 18.6.2. Business Segmentation
    • 18.6.3. Key Information
    • 18.6.4. SWOT Analysis

19. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Dermatological Drugs Market 2013-2018 (US$ billion)
  • Exhibit 3: Global Psoriasis Drugs Market 2013-2018 (US$ billion)
  • Exhibit 4: Global Acne Drugs Market 2013-2018 (US$ billion)
  • Exhibit 5: Global Dermatitis Drugs Market 2013-2018 (US$ billion)
  • Exhibit 6: Global Dermatological Drugs Market by Segmentation (revenue)
  • Exhibit 7: Global Dermatological Drugs Market by Segmentation (percentage)
  • Exhibit 8: Comparison of YOY Growth Rates among various Market Segments in Global Dermatological Drugs Market
  • Exhibit 9: Global Dermatological Drugs Market Segmentation by Types
  • Exhibit 10: Global Dermatological Drugs Market by Type 2013 (in percent)
  • Exhibit 11: Global Dermatological Drugs Market by Geographical Segmentation 2013
  • Exhibit 12: Business Segmentation of Johnson & Johnson Ltd.
  • Exhibit 13: Business Segmentation of Novartis AG
  • Exhibit 14: Business Segmentation of Valeant Pharmaceuticals International Inc.
Back to Top